A Network-Based Discovery of Prognostic Markers in Recurrent IDH wild-type Gliomas
preprint
OA: closed
Abstract
Background Isocitrate dehydrogenase wild-type (IDH wild-type) gliomas represents the most aggressive subtype of diffuse gliomas, characterized by therapeutic resistance and dismal prognosis. Despite advances in molecular classification, reliable prognostic biomarkers for these tumors remain limited, particularly for recurrent disease. This study aims to identify gene expression signatures associated with survival outcomes in recurrent IDH wild-type gliomas, with the goal of improving patient stratification and potential therapeutic targeting. Methods We analyzed gene expression data from 180 recurrent IDH wild-type glioma samples from the Glioma Longitudinal AnalySiS (GLASS) Consortium. Using multiple computational approaches including a novel network-based method (netSurvival) and various survival analysis techniques, we identified genes associated with patient survival outcomes. Results Our comprehensive analysis identify several gene expression markers that are significantly associated with survival outcomes in recurrent IDH wildtype gliomas. The AFT log normal model revealed that FN1, HIF3A, and EIF4B are associated with poorer survival (hazard ratios of 1.40, 1.49, and 1.54, respectively; p ¡ 0.05), while PTK2, CCND2, RAD51L3 RFFL, and MAX demonstrated protective effects (hazard ratios of 0.76, 0.78, 0.79, and 0.79, respectively; p ¡ 0.05). Five genes (KIF5C, LINC00632, B4GALNT3, HIF3A, and RAD51L3 RFFL) show significant differential expression between primary and recurrent tumors, with four having established functional roles in glioma pathobiology. Conclusion This study identifies a panel of gene expression markers with significant prognostic value in recurrent IDH wild-type gliomas. The differential impacts of these genes on survival outcomes provide insights into the biological heterogeneity underlying clinical behavior in these aggressive tumors. Particularly significant are the biomarkers associated with both survival outcomes and recurrence patterns, which may represent key drivers of disease progression. These findings represent an important step toward improved prognostic stratification and therapeutic targeting in IDH wild-type gliomas, addressing a critical unmet need in neuro-oncology.
Full text
2,402 characters
· extracted from
oa-doi-fallback
· 4 sections
· click to expand
Abstract
Background Isocitrate dehydrogenase wild-type (IDH wild-type) gliomas represents the most aggressive subtype of diffuse gliomas, characterized by therapeutic resistance and dismal prognosis. Despite advances in molecular classification, reliable prognostic biomarkers for these tumors remain limited, particularly for recurrent disease. This study aims to identify gene expression signatures associated with survival outcomes in recurrent IDH wild-type gliomas, with the goal of improving patient stratification and potential therapeutic targeting.
Methods
We analyzed gene expression data from 180 recurrent IDH wild-type glioma samples from the Glioma Longitudinal AnalySiS (GLASS) Consortium. Using multiple computational approaches including a novel network-based method (netSurvival) and various survival analysis techniques, we identified genes associated with patient survival outcomes.
Results
Our comprehensive analysis identify several gene expression markers that are significantly associated with survival outcomes in recurrent IDH wildtype gliomas. The AFT log normal model revealed that FN1, HIF3A, and EIF4B are associated with poorer survival (hazard ratios of 1.40, 1.49, and 1.54, respectively; p ¡ 0.05), while PTK2, CCND2, RAD51L3 RFFL, and MAX demonstrated protective effects (hazard ratios of 0.76, 0.78, 0.79, and 0.79, respectively; p ¡ 0.05). Five genes (KIF5C, LINC00632, B4GALNT3, HIF3A, and RAD51L3 RFFL) show significant differential expression between primary and recurrent tumors, with four having established functional roles in glioma pathobiology.
Conclusion
This study identifies a panel of gene expression markers with significant prognostic value in recurrent IDH wild-type gliomas. The differential impacts of these genes on survival outcomes provide insights into the biological heterogeneity underlying clinical behavior in these aggressive tumors. Particularly significant are the biomarkers associated with both survival outcomes and recurrence patterns, which may represent key drivers of disease progression. These findings represent an important step toward improved prognostic stratification and therapeutic targeting in IDH wild-type gliomas, addressing a critical unmet need in neuro-oncology.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
Revise labels such as figure 3 and supplementary illustrations.
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00